
EDE approves Rilzabrutinib for ITP treatment in UAE
Abu Dhabi: The Emirates Drug Establishment (EDE) has granted official approval for Rilzabrutinib, marking the first time this oral Bruton’s tyrosine kinase (BTK) inhibitor has been authorized in any country for the treatment of Immune Thrombocytopenia (ITP …